{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Nie H"],"funding":["Nanchang University Funding","National Natural Science Foundation of China","Jiangxi Provincial Health Commission"],"pagination":["116-135"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12063591"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(2)"],"pubmed_abstract":["<h4>Objective</h4>To assess the impact of lipid-lowering drugs (LLDs) and antihypertensive drugs on the risk of aortic diseases.<h4>Methods</h4>Mendelian randomization was utilized to analyse data from 500 000 participants in the UK Biobank to evaluate the effects of statins, PCSK9 inhibitors (PCSK9i), β-blockers, and calcium channel blockers on the risks of thoracic aortic aneurysm, abdominal aortic aneurysm, and aortic dissection (AD) using genetic variants as proxies. Real-world pharmacovigilance data from the FAERS (FDA Adverse Event Reporting System) database were used.<h4>Results</h4>PCSK9i and statins significantly reduced the risks of aortic aneurysms and AD, respectively. Furthermore, the two LLDs reduced the risk of aortic diseases through certain metabolites. Meanwhile, real-wor"],"journal":["European heart journal. Cardiovascular pharmacotherapy"],"pubmed_title":["Lipid-lowering and antihypertensive drugs on aortic disease risk: insights from Mendelian randomization analysis and real-world pharmacovigilance data."],"pmcid":["PMC12063591"],"funding_grant_id":["82460103","2024ZD005","82060095","2023efyA02"],"pubmed_authors":["Wang Q","Zhao W","Zhou W","Nie H"],"additional_accession":[]},"is_claimable":false,"name":"Lipid-lowering and antihypertensive drugs on aortic disease risk: insights from Mendelian randomization analysis and real-world pharmacovigilance data.","description":"<h4>Objective</h4>To assess the impact of lipid-lowering drugs (LLDs) and antihypertensive drugs on the risk of aortic diseases.<h4>Methods</h4>Mendelian randomization was utilized to analyse data from 500 000 participants in the UK Biobank to evaluate the effects of statins, PCSK9 inhibitors (PCSK9i), β-blockers, and calcium channel blockers on the risks of thoracic aortic aneurysm, abdominal aortic aneurysm, and aortic dissection (AD) using genetic variants as proxies. Real-world pharmacovigilance data from the FAERS (FDA Adverse Event Reporting System) database were used.<h4>Results</h4>PCSK9i and statins significantly reduced the risks of aortic aneurysms and AD, respectively. Furthermore, the two LLDs reduced the risk of aortic diseases through certain metabolites. Meanwhile, real-wor","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2026-07-01T03:21:25.965Z","creation":"2026-07-01T03:12:08.355Z"},"accession":"S-EPMC12063591","cross_references":{"pubmed":["39855644"],"doi":["10.1093/ehjcvp/pvaf001"]}}